PERAZODIN 75 TABLET 75 mg

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Active ingredient:

DIPYRIDAMOLE

Available from:

GOLDPLUS UNIVERSAL PTE LTD

ATC code:

B01AC07

Dosage:

75 mg

Pharmaceutical form:

TABLET, SUGAR COATED

Composition:

DIPYRIDAMOLE 75 mg

Administration route:

ORAL

Prescription type:

Prescription Only

Manufactured by:

REMEDICA LTD

Authorization status:

ACTIVE

Authorization date:

1988-04-27

Summary of Product characteristics

Limassol Industrial Estate, Aharnon Street, 3056 Limassol - Cyprus, EU
P18-0075R075SIN1
004324
PERAZODIN
PRODUCT NAME
Perazodin 75 mg coated tablets
NAME
AND
STRENGTH
OF
ACTIVE
SUBSTANCE
Each coated tablet contains 75 mg dipyridamole.
PRODUCT DESCRIPTION
Orange, round, sugar-coated tablets.
PHARMACOLOGICAL PROPERTIES
PHARMACODYNAMIC PROPERTIES
Pharmacotherapeutic group: Antithrombotic agents
ATC code: B01AC07
Dipyridamole inhibits the uptake of adenosine into
erythrocytes, platelets and endothelial cells in vitro
and in vivo; the inhibition amounts to 80% at its
maximum and occurs dose- dependently at therapeutic
concentrations (0.5-2 µg/mL). Consequently, there is an
increased concentration of adenosine locally to act on
the platelet A2-receptor, stimulating platelet adenylate
cyclase, thereby increasing platelet cAMP levels. Thus,
platelet aggregation in response to various stimuli such
as PAF, collagen and ADP is inhibited. Reduced platelet
aggregation
reduces
platelet
consumption
towards
normal levels. In addition, adenosine has a vasodilator
effect and this is one of the mechanisms by which
dipyridamole produces vasodilation.
Dipyridamole
inhibits
phosphodiesterase
(PDE)
in
various tissues. Whilst the inhibition of cAMP-PDE is
weak, therapeutic levels inhibit cGMP-PDE, thereby
augmenting the increase in cGMP produced by EDRF
(endothelium-derived relaxing factor, identified as NO).
Dipyridamole
also
stimulates
the
biosynthesis
and
release
of
prostacyclin
by
the
endothelium.
Dipyridamole
reduces
the
thrombogenicity
of
subendothelial
structures
by
increasing
the
concentration
of
the
protective
mediator
13-HODE
(13-hydroxyoctadecadienic acid)
PHARMACOKINETIC PROPERTIES
After dosing with the sugar-coated tablets there is a lag
time of 10-15 min associated with
disintegration
of
the
tablet
and
gastric
emptying.
Thereafter
the
drug
is
rapidly
absorbed
and
peak
plasma
concentrations
are
attained
after
1
hour.
Geometric mean (range) peak plasma concentrations at
steady state conditions with 75 mg t.d.s. were 1.86
µ